公开(公告)号：US20250064979A1

公开(公告)日：2025-02-27

申请号：US18715587

申请日：2022-12-02

Applicant: The Broad Institute, Inc. ,  President and Fellows of Harvard College

Inventor： David R. Liu ,  Aditya Raguram ,  Samagya Banskota ,  Meirui An

IPC: A61K48/00 ,  C12N7/00 ,  C12N9/12 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

Abstract: The present disclosure provides virus-like particles (VLPs) for delivering prime editors, and systems comprising such prime editor (PE) VLPs. The present disclosure also provides polynucleotides encoding the PE-VLPs described herein, which may be useful for producing said PE-VLPs. Also provided herein are methods for editing the genome of a target cell by introducing the presently described PE-VLPs into the target cell. The present disclosure also provides fusion proteins that make up a component of the PE-VLPs described herein, as well as polynucleotides, vectors, cells, and kits.

公开(公告)号：US20250064976A1

公开(公告)日：2025-02-27

申请号：US18948601

申请日：2024-11-15

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology

Inventor： Feng Zhang ,  Victoria Madigan ,  Yugang Zhang ,  Rumya Raghavan ,  Max Wilkinson ,  Guilhem Faure ,  Rhiannon Macrae

IPC: A61K48/00 ,  C12N7/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86

Abstract: Described herein are engineered paraneoplastic Ma protein (PNMA) capable of forming a capsid. In some embodiments, the engineered PNMA proteins comprise one or more modifications that enhance binding or loading of a cargo into the capsid, one or more modifications that modify cell-specificity of the capsid, one or more modifications that enhance intracellular delivery of the capsid, or a combination thereof. Also described herein are delivery systems comprising capsids comprising an engineered PNMA protein and a cargo.

公开(公告)号：US20250064920A1

公开(公告)日：2025-02-27

申请号：US18790098

申请日：2024-07-31

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Grace Albanese ,  Aemro KASSA ,  Annika KRAEMER-KUEHL ,  Stephane LEMIERE

IPC: A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

公开(公告)号：US20250064919A1

公开(公告)日：2025-02-27

申请号：US18726909

申请日：2023-01-05

Applicant: Board of Regents, The University of Texas System

Inventor： Alexander Bukreyev ,  Philipp A. Ilinykh ,  Sivakumar Periasamy ,  Kai Huang

IPC: A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61P31/14 ,  C12N7/00

Abstract: The disclosure is directed to a new human parainfluenza virus (HPIV)/SARS-CoV-2 vaccine or vaccine construct/polynucleotide. Specifically, the HPIV is a Human parainfluenza virus type 3 (HIPV3), and the vaccine construct encoding a SARS-CoV-2 spike protein (S protein), that is a SARS-CoV-2 S protein S1 subunit and/or a SARS-CoV-2 S protein receptor binding domain (RBD), in certain aspects the vaccine or vaccine construct is administered via intranasal administration.

公开(公告)号：US20250059560A1

公开(公告)日：2025-02-20

申请号：US18719792

申请日：2022-12-15

Applicant: Sana Biotechnology, Inc.

Inventor： Noelle COLANT ,  Kaely B. GALLAGHER ,  Yonatan Y. LIPSITZ ,  Jeffrey John UNDERHILL

IPC: C12N15/86 ,  C12N7/00

Abstract: Provided herein are methods of producing lipid membrane bound particles, such as lentiviral vectors, that contain one or more Paramyxovirus envelope proteins in the lipid bilayer. Also provided are lipid membrane bound particles containing one or more Paramyxovirus envelope proteins in the lipid bilayer. In some embodiments, the one or more Paramyxovirus envelope protein is a Nipah virus (NiV) protein G or F or a biologically active portion or retargeted fusion thereof. In some embodiments, the lipid membrane bound particle is a lentiviral vector. Also provided are related compositions, kits and systems in connection with the provided methods.

公开(公告)号：US20250057934A1

公开(公告)日：2025-02-20

申请号：US18723268

申请日：2022-12-23

Applicant: INTERVET INC.

Inventor： Martin PIEST ,  Marc THEELEN ,  Franciscus Gerardus Antonios MANDERS ,  Maarten Hendrik WITVLIET

IPC: A61K39/135 ,  A61K9/107 ,  A61K39/00 ,  A61K39/39 ,  B82Y5/00 ,  C12N7/00

Abstract: The present invention relates to the field of vaccinology, more specifically of veterinary vaccinology. In particular, the invention relates to an adjuvant composition comprising an emulsion of water, tocopherol or a pharmaceutically acceptable ester thereof, and a polyethoxyethylene cetostearyl ether as an emulsifier. Said adjuvant composition can be used for formulating a vaccine, particularly an emulsion vaccine, comprising a bacterial, parasitic, or viral antigen. The resulting vaccine composition can be used in a method of protecting a human or animal target against infection and/or disease caused by a pathogen, particularly caused by a bacterium, parasite or virus. The invention further relates to methods for the manufacture of such adjuvant compositions and for the manufacture of such vaccine composition.

公开(公告)号：US12227769B2

公开(公告)日：2025-02-18

申请号：US17309038

申请日：2019-10-18

Applicant: The University of Chicago ,  Nationwide Children's Hospital ,  The Ohio State University

Inventor： Jianrong Li ,  Mark E. Peeples ,  Chuan He ,  Stefan Niewiesk ,  Mijia Lu ,  Miaoge Xue ,  Zijie Zhang ,  Boxuan Zhao

IPC: A61K35/76 ,  C12N7/00

Abstract: The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.

公开(公告)号：US12227755B2

公开(公告)日：2025-02-18

申请号：US17846817

申请日：2022-06-22

Applicant: UNIVERSITÄT ZÜRICH

Inventor： Daniel D. Pinschewer ,  Lukas Flatz ,  Andreas Bergthaler ,  Rolf Zinkernagel

IPC: C12N15/86 ,  A61K35/76 ,  A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  A61K39/00

Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.

公开(公告)号：US20250051421A1

公开(公告)日：2025-02-13

申请号：US18741447

申请日：2024-06-12

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: C07K14/715 ,  A61K39/00 ,  A61P35/00 ,  C07K16/40 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/86

Abstract: Provided herein are constitutively active chimeric cytokine receptors (CACCRs). When present on chimeric antigen receptor (CAR)-bearing immune cells, such CACCRs allow for increased immune cell activation, proliferation, persistence, and/or potency. Also provided are methods of making and using the CACCRs described herein.

公开(公告)号：US20250049916A1

公开(公告)日：2025-02-13

申请号：US18719415

申请日：2022-06-06

Applicant: NEWISH TECHNOLOGY (BEIJING) CO., LTD. ,  INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES

Inventor： Xiaofang WANG ,  Jiandong JIANG ,  Yanling YAO ,  Zhongjie SUN ,  Lulu WANG ,  Xudong WANG ,  Defang LIU ,  Hailong QI

IPC: A61K39/39 ,  A61K39/12 ,  C07K14/52 ,  C12N7/00 ,  C12N15/62

Abstract: The chemotactic binding ability of CCL13 and an immune cell surface receptor such as DC cells is used to transport different antigenic proteins to the surface of the DC cells, the efficiency of phagocytosis, processing, and presentation of various antigenic proteins by the DC cells is improved, and the effect of preventing and treating related diseases of the antigenic proteins is enhanced. A T2 sequence is further added in an antigen, such that the immune effect can be enhanced.